Why Context Therapeutics Inc.’s (CNTX) Stock Is Down 28.87%
As of Thursday, August 06, Context Therapeutics Inc.’s CNTX share price has dipped by 28.87%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Commentary & Analysis
Why Context Therapeutics Inc.’s (CNTX) Stock Is Down 24.37%
As of Thursday, August 06, Context Therapeutics Inc.’s CNTX share price has dipped by 24.37%, which has investors questioning if this is right time to buy.Omar Beirat
Why Context Therapeutics Inc.’s (CNTX) Stock Is Down 6.78%
As of Tuesday, July 28, Context Therapeutics Inc.’s CNTX share price has dipped by 6.78%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Context Therapeutics Inc.’s (CNTX) Stock Is Up 7.12%
As of Friday, July 10, Context Therapeutics Inc.’s CNTX share price has surged by 7.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Context Therapeutics Inc.’s (CNTX) Stock Is Down 7.40%
As of Wednesday, July 08, Context Therapeutics Inc.’s CNTX share price has dipped by 7.40%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CNTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $27.9 | $519.2 | 12% |
|
| Shares Out (Mil) | 95.2 | 42.8 | 61% |
|
| Institutional Ownership | 96.9% | 82.8% | 71% |
|
| Float (Mil) | 63.7 | 44.4 | 52% |
|
| Beta | 1.74 | 0.71 | 87% |
|
| Avg Daily Volume (000s) | 893 | 394 | 68% |
|
| Price Change (52-week) |
(73.3%) | 60.2% | 10% |
|
| Growth | CNTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (49.5%) | (2.0%) | 7% |
|
| EPS (5yr) | 37.4% | 15.0% | 87 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (23.8%) | (15.1%) | 27% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 7 | |
| Current EPS | ($0.108) | ($0.460) | ($0.436) | |
| Month Ago EPS | ($0.108) | ($0.460) | ($0.436) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.096) | ($0.390) | ($0.431) | |
| Year/Year Chg | (29.4%) | 21.1% | 35.3% | |
| Financials | CNTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($46) | ($11) | 17% |
|
| EPS (TTM) | ($0.483) | ($0.700) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($7) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 10% |
|
| Enterprise Value (Q1) (Mil) | $3 | $494 | 5% |
|
| Valuation | CNTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.72 | 2.31 | 15% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CNTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (69.0%) | (22.2%) | 9% |
|
| ROE | (76.1%) | (21.4%) | 11% |
|
| Liabilities to Assets | 17.3% | 32.8% | 11% |
|
| F-Score | 2 | 3 | 7% |
|
Context Therapeutics Inc. did not pass any screens on 10/9/2026.
